AIM ImmunoTech Inc.
AIM ImmunoTech Inc.
Your view on AIM
Overview
What the company does, where it operates, and who runs it.
About AIM ImmunoTech Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas K. Equels
- Headquarters
- 2117 SW Highway 484, Ocala, FL, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Thomas K. Equels
- Headquarters
- 2117 SW Highway 484, Ocala, FL, US
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States.
The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease.
It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente.
The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for AIM ImmunoTech Inc. from FRC's valuation model, read against the market price. AIM last traded at $0.15; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for AIM ImmunoTech Inc.. Starting points for AIM ImmunoTech Inc.: EPS -$0.83, beta 1.31 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for AIM ImmunoTech Inc.. AIM ImmunoTech Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for AIM ImmunoTech Inc.. Trailing twelve-month EPS for AIM ImmunoTech Inc. stands at -$0.83. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Analyst Ratings
- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.14 | -$0.15 | -$0.86 | -$0.54 |
| Low estimate | -$0.14 | -$0.15 | -$1.03 | -$0.64 |
| High estimate | -$0.14 | -$0.15 | -$0.69 | -$0.44 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$1.34 | -$0.69 | -$8.62 | — |
| Growth | +89.5% | +78.3% | +90.0% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $25462.00 | $25197.00 | $74000.00 | $100000.00 |
| Low estimate | $25462.00 | $25197.00 | $62942.00 | $85057.00 |
| High estimate | $25462.00 | $25197.00 | $85057.00 | $114942.00 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | $25000.00 | $22000.00 | $88000.00 | — |
| Growth | +1.8% | +14.5% | -15.9% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for AIM ImmunoTech Inc.. AIM ImmunoTech Inc. has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
AIM ImmunoTech Inc. valued side by side against its closest peers. AIM ImmunoTech Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold AIM ImmunoTech Inc., and how their positions are changing. At a $5.9M market value, institutional positions materially move AIM ImmunoTech Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by AIM ImmunoTech Inc. executives and directors. Shares of AIM ImmunoTech Inc. have traded between $1.31 and $36.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for AIM ImmunoTech Inc.. Coverage tracks AIM ImmunoTech Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of AIM ImmunoTech Inc.